23:41 , Jun 28, 2019 |  BC Extra  |  Financial News

June 28 Financial Quick Takes: Karuna rises after IPO; plus Chi-Med, BeiGene and more

Karuna spikes in first-day trading on NASDAQ  PureTech Health plc (LSE:PRTC) portfolio company Karuna Therapeutics Inc. (NASDAQ:KRTX) climbed $4.02 (25%) to $20.02 Friday after raising $89.2 million through the sale of 5.6 million shares at...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
20:36 , May 31, 2019 |  BC Extra  |  Financial News

New IPO filings include Adaptive, Morphic

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday. Adaptive Biotechnologies Corp. (Seattle, Wash.)...
14:19 , May 14, 2019 |  BC Innovations  |  Distillery Techniques

A mouse model to screen therapies for Williams syndrome

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Transgenics and knockouts GTF2I-deficient mice could be used to screen therapies for Williams syndrome, which is caused by gene deletions on chromosome 7 that lead to learning and cardiovascular problems....
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
16:12 , Apr 5, 2019 |  BC Week In Review  |  Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

Circassia said FDA approved Duaklir Pressair aclidinium bromide/formoterol fumarate to treat chronic obstructive pulmonary disease. The agency also accepted for review an sNDA for Tudorza Pressair aclidinium bromide to include on its label clinical data...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
14:06 , Mar 18, 2019 |  BC Extra  |  Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...